CYduct Diagnostics, Inc. (CYDX)
OTC Markets OTCID
Fundamentals
Valuation and ratings
CYduct Diagnostics, Inc. trades at USD2.70. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About CYduct Diagnostics, Inc.
CYduct Diagnostics, Inc., a healthcare company, develops, produces, and markets medical devices for the assessment, identification, diagnosis and treatment of breast cancer. The company offers HALO system, a noninvasive device that utilizes proprietary technology to obtain breast fluid; and MammoView, a fiberoptic technology with the ability to view and collect cells and other abnormalities. It also provides women and clinicians with technology that will lead the Intraductal approach to breast cancer and improvement in breast healthcare. The company was formerly known as Solos Endoscopy, Inc. and changed its name to CYduct Diagnostics, Inc. in December 2020. CYduct Diagnostics, Inc. was incorporated in 1986 and is based in Westport, Connecticut.
The full research page for CYDX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.